(Q40270911)

English

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

scientific article published on January 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

Lila Adnane

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Pamela A Trail

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Ian Taylor

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Scott M Wilhelm

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

0 references

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Methods in Enzymology

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

407

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

597-612

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dominant negative mutants of mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of BRAF mutation in primary uveal melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006: early clinical data in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

B-RAF is a therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ras/Raf signalling and emerging pharmacotherapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

When kinases meet mathematics: the systems biology of MAPK signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and discovery of small molecules targeting raf-1 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of a novel Raf kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High frequency of BRAF mutations in nevi

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

RAF/RAS oncogenes and mismatch-repair status

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the mitogen-activated protein kinase cascade to treat cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Raf kinase inhibitors in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006: preclinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of the BRAF gene in benign and malignant melanocytic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2805%2907047-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0076-6879(05)07047-3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40270911&oldid=1891422661"